Meanwhile, MYEF2 has been characterized as a downstream target modulated by the Wnt/β-catenin pathway; since inhibition of Wnt/β-catenin signaling suppresses a number of cancers (e.g. multiple myeloma, colorectal cancer, etc.)[47], the genes regulated by Wnt/β-catenin may provide insights into the mechanisms of cancer developments and therapies. The gene discussed is MYEF2; the disease is plasma cell myeloma.